Form 4: Oncology Institute CMO Acquires Shares via RSU Vesting

The Oncology Institute's Chief Medical Officer, Yale Podnos, acquired 1,508 shares of common stock through vested RSU awards.

Summary

• Yale Podnos, Chief Medical Officer of The Oncology Institute, Inc. (TOI), acquired common stock.
• The transactions occurred on November 12, 2025.
• A total of 1,508 shares were acquired in two separate transactions (306 shares and 1,202 shares).
• The shares were acquired at a price of $0.00, representing fully vested RSU awards net of withholding tax obligations.
• Following these transactions, Yale Podnos beneficially owns 235,844 shares of common stock directly.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The acquisition of shares by a key executive, even if through RSU vesting, generally indicates a positive alignment of interests with shareholders. However, the $0.00 price point (compensation) makes it less impactful than a direct cash purchase, hence a moderate positive score.

Positives

• Insider acquisition of shares, even if through RSU vesting, can signal confidence in the company's future.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary acquisition.

Negatives

• The shares were acquired at $0.00, indicating they are compensation (RSU vesting) rather than an open market purchase with personal capital, which dilutes the positive signal compared to a cash purchase.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to equity compensation for an executive in the healthcare/oncology sector. It does not provide specific industry context beyond that.

Stakeholder Impact

• Shareholders may view the executive's increased ownership as a positive sign of alignment with shareholder interests.
• Employees may see this as a routine part of executive compensation packages.

Key Dates

Recommendation

This Form 4 reports a routine vesting of Restricted Stock Units (RSUs) for a key executive, not a discretionary open market purchase. While it increases insider ownership, it does not provide new fundamental information about the company's performance or strategic direction that would warrant a change in investment recommendation. It is an expected compensation event.

Keywords

Oncology Institute, TOI, Yale Podnos, Chief Medical Officer, Insider Trading, Form 4, SEC Filing, Stock Acquisition, RSU, Restricted Stock Units, Equity Compensation, Rule 10b5-1